The average one-year price target for Artiva Biotherapeutics (NasdaqGM:ARTV) has been revised to $27.74 / share. This is an increase of 60.00% from the prior estimate of $17.34 dated April 25, 2026.

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) are rising Friday after the San Diego-based biotech company shared a milestone regulatory update. What To Know: Artiva said the Food and Drug ...

Artiva Biotherapeutics Inc. Annual stock financials by MarketWatch. View the latest ARTV financial statements, income statements and financial ratios.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

** When you buy products through the links on our site, we may earn a commission that supports NRA's mission to protect, preserve and defend the Second Amendment. ** Over a two-year period, Colt ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

President and CEO of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), Aslan Fred, sold 6,375 shares of common stock on November 17, 2025, according to a Form 4 filing with the Securities and Exchange ...

Artiva Biotherapeutics (ARTV) is maintained as a "Buy," driven by FDA alignment for a single phase 3 trial of AlloNK plus ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.